Health and Fitness Health and Fitness
Fri, December 2, 2011
Thu, December 1, 2011
Wed, November 30, 2011
[ Wed, Nov 30th 2011 ] - Market Wire
Watson Launches Generic LIPITOR
Tue, November 29, 2011
Mon, November 28, 2011
Sun, November 27, 2011
Fri, November 25, 2011
Thu, November 24, 2011
Wed, November 23, 2011
[ Wed, Nov 23rd 2011 ] - Market Wire
00 a.m. EST
Tue, November 22, 2011
[ Tue, Nov 22nd 2011 ] - Market Wire
BD Board Increases Dividend
Mon, November 21, 2011
Sun, November 20, 2011
Fri, November 18, 2011

Optimer Pharmaceuticals to Webcast Investor and Analyst Reception on December 5th


//health-fitness.news-articles.net/content/2011/ .. estor-and-analyst-reception-on-december-5th.html
Published in Health and Fitness on Monday, November 28th 2011 at 5:16 GMT by Market Wire   Print publication without navigation


Optimer Pharmaceuticals to Webcast Investor and Analyst Reception on December 5th -- iv class='Section1'>  SAN DIEGO, Nov. 28, 2011  /PRNewswire/ --

Optimer Pharmaceuticals to Webcast Investor and Analyst Reception on December 5th

[ ]

 

SAN DIEGO, Nov. 28, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: [ OPTR ]) will host investors and analysts in New York City on December 5, 2011 for a corporate overview and update with a focus on its commercial strategy and launch of DIFICID.  A live webcast of the event will begin at 8:30 a.m. Eastern time and will be accessible on the Investors page of the Company's website at [ www.optimerpharma.com ]. A replay will be available for 90 days.

(Logo: [ http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ])

Speakers will include members of the executive management team as well as guest speaker Roy F. Chemaly, M.D., MPH, University of Texas MD Anderson Cancer Center.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has developed and is commercializing DIFICID™ (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer is seeking marketing authorization for fidaxomicin in the European Union and Canada and is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem, including Asia. Additional information can be found at [ http://www.optimerpharma.com ].

Contacts

Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
858-909-0736

Canale Communications
Jason I. Spark, Senior Vice President
619-849-6005

 

SOURCE Optimer Pharmaceuticals, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.optimerpharma.com ]


Publication Contributing Sources